Delivery Order SPE2DB20D1004-SPE2DB24FG6L2

Award Date 8/12/24
Potential Completion Date 8/13/24
Potential Value $5.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 mg tablets. The contract has a ceiling value of $50,250.67 and a period of performance through November 27, 2024. It is a firm fixed-price contract, with no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET in quantities of 30 with a ceiling value of $5,507.08. The contract is a firm fixed price, non-set-aside award with a performance period through July 2, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET UU 30S. The contract has a firm-fixed price and a ceiling value of $7,586.53. It is not set aside and runs through May 19, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999.00. This IDC provides a comprehensive...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 mg tablets. The ceiling value of the contract is $14,383.73, and the ultimate completion date is October 15, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of XELJANZ XR 11 MG TABLET, a medication, with a ceiling value of $5,922.73 and a period of performance through July 2, 2025. The contract is a firm fixed-price type and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET. The contract has a firm fixed price of $30,050.50 and a completion date of January 17, 2025. The contract was not set aside for any specific business type. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XELJANZ XR 11 MG TABLET, a specialty pharmaceutical product, and has a ceiling value of $3,472.13. The contract is a firm fixed price agreement and has an ultimate completion date of July 11, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product, with a ceiling value of $3,118.90 and a performance period ending on May 15, 2025. The contract is a Firm Fixed Price, non-set-aside award. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,678.35, is for the delivery of 4,567,859,053 units of the medication XELJANZ XR 11 MG TABLET. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 10, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ 5 MG TABLET. The contract has a ceiling value of $13,105.95 and a completion date of February 27, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also holds a significant $999,999,999 Indefinite...
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB24FG6L2
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 mg tablets. The contract has a ceiling value of $5,276.73 and runs through August 13, 2024. It is a firm fixed-price contract, with no set-aside designation.

AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and valid through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The current delivery order is likely part of this broader IDC, which covers critical medical commodities such as specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas.

Generated 2/27/25, 11:16 AM